Market Place
Sourcing Support
Bayer, Novo separately opt to discontinue their Aliqopa, Levemir
10 Nov 2023 //
FIERCE PHARMA
Bayer to pull follicular lymphoma drug Aliqopa from US market
08 Nov 2023 //
ENDPTS
Bayer Submits Regulatory Applications for Aliqopa and rituximab Combo
21 Jun 2021 //
BUSINESSWIRE
Investigational Combination of Aliqopa® and rituximab Significantly
16 Apr 2021 //
BUSINESSWIRE
Investigational Combination of Aliqopa® (copanlisib) and rituximab
09 Apr 2021 //
BUSINESSWIRE
Pharming deal shows there`s still life in struggling cancer drug class
16 Aug 2019 //
BIOPHARMADIVE
FDA breakthrough therapy designation granted for Bayer’s Aliqopa
30 May 2019 //
PHARMA TIMES
TG Therapeutics’ shares jump as umbralisib wins FDA’s breakthrough status
22 Jan 2019 //
ENDPTS
Novartis considers filings for PI3K drug in breast cancer
24 Aug 2018 //
PMLIVE
Novartis trial win lifts profile of new breast cancer drug
23 Aug 2018 //
REUTERS
Novartis punts a late-stage PI3K drug to China’s biotechs
12 Jul 2018 //
ENDPTS
Popular keto diet to be tested in humans to check effect of weak PI3K drugs
09 Jul 2018 //
ENDPTS
Roche dumps PhIII taselisib after harsh side effects for breast cancer
03 Jun 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.